Molecular and pathophysiological heterogeneity of autoimmune diabetes: implications for precision medicine
People with autoimmune diabetes (AD) are at higher risk of death due to the development of its acute and long-term sequelae. The process towards a cure for AD should encompass the identification of new pathways to prevent beta-cell failure and complications. A deep knowledge of AD heterogeneity is essential to understand and tackle the processes leading to disease onset and progression. In this project, we have the unique opportunity to compare molecular and pathophysiological mechanisms of AD between subjects with aggressive or slowly progressive beta-cell destruction through a translational approach encompassing basic and clinical research activities.